Outlook Therapeutics (OTLK) vs PepGen (PEPG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
PepGen (PEPG) has outperformed Outlook Therapeutics (OTLK) over the past year, losing 47.9% versus a loss of 51.3%. PepGen is the larger company by market cap ($181.2 million vs $145.8 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OTLK | PEPG |
|---|---|---|
| Share price | $0.5989 | $2.62 |
| Market cap | $145.80M | $181.22M |
| 1-day change | +6.19% | +10.08% |
| YTD return | -62.09% | -59.75% |
| 1-year return | -51.31% | -47.91% |
| 5-year return | -98.58% | — |
| EPS (TTM) | $-0.74 | $-1.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.54 | $7.80 |
| 52-week low | $0.161 | $1.31 |
| Distance from 52-week high | -76.40% | -66.41% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +739.87% | +288.93% |
| Average volume | 13.43M | 923.99K |
| Shares outstanding | 243.45M | 69.17M |
| Employees | 17 | 57 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Outlook Therapeutics
OTLK stock →Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.
Healthcare · Biotechnology · 17 employees
About PepGen
PEPG stock →PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1.
Healthcare · Biotechnology · 57 employees
OTLK vs PEPG FAQ
Which is bigger, Outlook Therapeutics or PepGen?
PepGen (PEPG) is larger, with a market capitalization of $181.22M compared with $145.80M for Outlook Therapeutics (OTLK).
Which stock has performed better over the past year, OTLK or PEPG?
PEPG returned -47.91% over the past 12 months, compared with -51.31% for OTLK (price return, excluding dividends). Past performance does not predict future results.
Are Outlook Therapeutics and PepGen in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.